HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 7, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for terconazole vaginal cream, 0.8%.
HAWTHORNE, N.Y., Mar 8, 2004 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Phenytoin Oral Suspension USP, 125
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb. 17, 2004-- 20 Consecutive Years of Record Sales; 6 Consecutive Years of Record Net Income 2003 Highlights -- Q4 Sales Increase 43% to $88.6 million -- Q4 Gross Profit Increases 61% to $62.1 million -- Q4 Net Income Increases 29% to $16.6 million, or $0.56 per
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 8, 2004-- OTC Formulation Extends Line of Spill-Resistant ElixSure(TM) Pediatric Products Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S.
Hawthorne, New York, January 8, 2004 – Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced that its U.S. affiliate has expanded its distribution capacity with the purchase of a modern, 315,000 square foot distribution center on 25 acres of land in South Brunswick, New Jersey.
HAWTHORNE, N.Y., Dec 10, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced that ElixSure(TM) spill-resistant children's medicines, recently launched in the U.S. by Taro Consumer Healthcare Products, have received a 2003 Good Buy Award from the Good
HAWTHORNE, N.Y., Dec 9, 2003 (BUSINESS WIRE) -- Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) reported today that its U.S. affiliate has received approvals from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Applications ("ANDAs") for betamethasone dipropionate
Hawthorne, New York, December 1, 2003 – Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO) today announced the completion of a $50 million offering of long-term, non-convertible debt to institutional investors in Israel. Approximately $47 million of the debt issued in the offering was received in
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 12, 2003--Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received tentative approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for fluconazole tablets
Alerts are e-mailed to you whenever certain new company information is posted to this site.
